Design and Development of Theranostic Nanomedicines - Nanotechnology for Biomedical Imaging and Diagnostics - page 445

to be used to probe drug action in the subject as the drug is released. if the nanomedi-
cine formulation is to become a tool for personalized medicine, more information is
needed than just whether the drug delivery system reached its target or not. as we
mentioned earlier, the question of cost and manufacturing feasibility is quite impor-
tant to keep asking when theranostic nanomedicines are considered and designed.
no patient would be able to afford a medicine that is too costly to produce no matter
how much personalization it may offer. Many examples of multifunctional nanopar-
ticles have its value for research, but may not always lead toward nanomedicine goal
if manufacturing and safety are not fully considered. We do not wish to say that
highly innovative nanomedicine formulations to date have no chance of reaching the
clinic but caution that in their design pharmaceutical principles must be implemented
early on. it is also wise to consider formulation platforms well tested as drug delivery
systems or imaging agents with known clinical use for theranostic nanomedicine
formulation. Those existing formulations come to theranostic field with already
well-described manufacturing scale production know-how, patient safety, pharmaco-
kinetics. We identified that for theranostic development liposomes, polymeric
nanoparticles, and nanoemulsions may be pharmaceutically the most attractive
platform. as nanodispersions are being developed to improve drug delivery, taking
those into consideration for theranostic development is another wise approach.
Finally, we also want to point out that theranostic principles could be applied to dos-
age forms beyond injectable nanosystems. oral drug delivery or implants could
benefit from theranostic design principles.
at the end, we would like to see theranostics as the personalized nanomedicines
in the future and hope the efforts already existing in engineering, chemistry, material
science, and pharmaceutics, when combined into joint forces, can lead us there faster.
references
[1] etheridge Ml, Campbell sa, erdman ag, haynes Cl, Wolf sM, McCullough J. The big
picture on nanomedicine: the state of investigational and approved nanomedicine products.
nanomedicine 2013; 9 :1-14.
[2] Wang r, Billone ps, Mullett WM. nanomedicine in action: an overview of cancer nano-
medicine on the market and in clinical trials. J nanomater 2013; 2013 :1-12.
[3] patel sK, Zhang Y, pollock Ja, Janjic JM. Cyclooxgenase-2 inhibiting perfluoropoly
(ethylene glycol) ether theranostic nanoemulsions-in vitro study. plos one 2013; 8 :e55802.
[4] o'hanlon Ce, amede Kg, o'hear Mr, Janjic JM. nir-labeled perfluoropolyether
nanoemulsions for drug delivery and imaging. J Fluor Chem 2012; 137 :27-33.
[5] Kievit FM, Zhang M. surface engineering of iron oxide nanoparticles for targeted cancer
therapy. acc Chem res 2011; 44 :853-862.
[6] Jain TK, Foy sp, erokwu B, Dimitrijevic s, Flask Ca, labhasetwar v. Magnetic resonance
imaging of multifunctional pluronic stabilized iron-oxide nanoparticles in tumor-bearing
mice. Biomaterials 2009; 30 :6748-6756.
[7] santra s, Kaittanis C, grimm J, perez JM. Drug/dye-loaded, multifunctional iron oxide
nanoparticles for combined targeted cancer therapy and dual optical/magnetic resonance
imaging. small 2009; 5 :1862-1868.